☆ 4.8 Article

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

NATURE COMMUNICATIONS (2022)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai et al.

Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.

CELL (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Sandile Cele et al.

Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

Add to Collection

News Item Biotechnology & Applied Microbiology

A tale of two antiviral targets - and the COVID-19 drugs that bind them

Megan Cully

Summary: The FDA is considering authorizations for Pfizer's paxlovid and Merck & Co.'s molnupiravir, the first two oral COVID-19 antivirals.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Article Cell Biology

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Benjamin L. Sievers et al.

Summary: This study demonstrates that the Omicron variant of SARS-CoV-2 is the most resistant to neutralization, and antibody responses may be reduced in vaccinated pregnant women, highlighting the need to maximize vaccine responses in this population.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Virology

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188

Gordon J. Lockbaum et al.

Summary: Viral proteases are crucial enzymes for the maturation of human pathogenic viruses, and ML188, a non-covalent inhibitor, shows more potency against SARS-CoV-2 M-pro. These non-covalent inhibitors play a critical role in the design of DAAs for treating COVID-19.

VIRUSES-BASEL (2021)

Add to Collection

Editorial Material Chemistry, Medicinal

Early Returns on Small Molecule Therapeutics for SARS-CoV-2

Mark N. Namchuk

Summary: The scientific community's unprecedented response to the COVID-19 pandemic has led to significant progress in identifying potential treatments, providing valuable insights for future pandemic preparedness.

ACS INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

Chun-Hui Zhang et al.

Summary: Starting from known drugs, the study redesigned perampanel into potent noncovalent inhibitors of SARS-CoV-2 main protease with ca. 20 nM IC50 values. Free-energy perturbation calculations and high-resolution X-ray crystal structures guided the design efforts and rapid development of effective analogues. Cell-based antiviral assays confirmed the potential of the compounds for COVID-19 treatment, highlighting the power of computational chemistry in drug discovery.

ACS CENTRAL SCIENCE (2021)

Add to Collection

Review Chemistry, Multidisciplinary

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

Yingzhu Li et al.

Summary: The report examines a significant number of vaccine candidates for the COVID-19 pandemic that emerged last year, discussing their technological advantages and disadvantages, the use of adjuvants and delivery systems, and providing insights into their future direction.

ACS CENTRAL SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode

Gordon J. Lockbaum et al.

Summary: Rupintrivir targets the 3C cysteine proteases of picornaviruses but shows weak activity against the 3C-like protease of SARS-CoV-2. The study found that Rupintrivir binds uniquely to the active site of the SARS-CoV-2 main protease, potentially offering a novel approach to inhibiting cysteine proteases.

BIOCHEMISTRY (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Desaboini Nageswara Rao et al.

Summary: By designing and synthesizing compounds with different chemical scaffolds at the P2 and P4 positions, researchers developed pan-genotypic HCV NS3/4A protease inhibitors with excellent antiviral activity and improved drug resistance profiles.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Multidisciplinary Sciences

Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential

Bjoern Meyer et al.

Summary: The study investigated the proteolytic cleavage profile of viral and cellular proteins in SARS-CoV-2 replication using mass spectrometry, identifying previously unknown cleavage sites in viral proteins and potential substrates of main and papain-like proteases. siRNA depletion of certain cellular proteins inhibited SARS-CoV-2 replication, and drugs targeting specific proteins showed a dose-dependent reduction in virus titres, providing insights for developing targeted strategies to inhibit SARS-CoV-2 and treat COVID-19.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Chemistry, Medicinal

Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease

Elizabeth A. MacDonald et al.

Summary: The main protease (Mpro) of SARS-CoV-2 plays a key role in viral replication by cleaving viral polyproteins at specific sites, and its interactions with substrates can have significant effects on catalytic efficiency. The study provides insights into potential targets for antiviral drug design and highlights the importance of finely tuned substrate-dependent catalytic parameters in the coronavirus lifecycle.

ACS INFECTIOUS DISEASES (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Clinical evidence that the pandemic from 1889 to 1891 commonly called the Russian flu might have been an earlier coronavirus pandemic

Harald Brussow et al.

Summary: Medical reports from late 19th century Britain and Germany on patients with the 1889-1891 Russian flu show similarities with COVID-19, such as multisystem affections, respiratory, gastrointestinal, and neurological symptoms, and a protracted recovery. Mortality was higher in elderly subjects, while children were less affected. Trans-species infection between pet animals or horses and humans was also noted, possibly linked to a broad host range bovine coronavirus around 1890.

MICROBIAL BIOTECHNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor

Daniel Zaidman et al.

Summary: The computational pipeline presented in this study identifies irreversible inhibitors that can bind covalently to cysteine, showing promise for drug development in recent prospective evaluations.

CELL CHEMICAL BIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The structure of Plasmodium falciparum hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase reveals the basis of sulfa resistance

Penchit Chitnumsub et al.

FEBS JOURNAL (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for strand-transfer inhibitor binding to HIV intasomes

Dario Oliveira Passos et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Wenhao Dai et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Linlin Zhang et al.

SCIENCE (2020)

Add to Collection

Article Microbiology

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors

Ashley N. Matthew et al.

MBIO (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Zhenming Jin et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

Daniel W. Kneller et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Chemistry, Medicinal

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

Robert L. Hoffman et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Review Infectious Diseases

Influenza and antiviral resistance: an overview

Temi Lampejo

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors

Aysegul Ozen et al.

CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)

Add to Collection

Article Chemistry, Medicinal

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors

Xue Zhi Zhao et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

Add to Collection

Article Chemistry, Medicinal

Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS

Arun K. Ghosh et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Add to Collection

Article Chemistry, Multidisciplinary

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease

Djade I. Soumana et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Improving Viral Protease Inhibitors to Counter Drug Resistance

Nese Kurt Yilmaz et al.

TRENDS IN MICROBIOLOGY (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance

Akbar Ali et al.

ACS CHEMICAL BIOLOGY (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

G. Madhavi Sastry et al.

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2013)

Add to Collection

Article Infectious Diseases

HIV drug resistance: problems and perspectives

Pleuni S. Pennings

INFECTIOUS DISEASE REPORTS (2013)

Add to Collection

Article Medicine, General & Internal

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Ali Moh Zaki et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Microbiology

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

Keith P. Romano et al.

PLOS PATHOGENS (2012)

Add to Collection

Article Infectious Diseases

Systematic review of influenza resistance to the neuraminidase inhibitors

Kristian Thorlund et al.

BMC INFECTIOUS DISEASES (2011)

Add to Collection

Review Gastroenterology & Hepatology

Hepatitis C virus resistance to protease inhibitors

Philippe Halfon et al.

JOURNAL OF HEPATOLOGY (2011)

Add to Collection

Article Virology

Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease

Keith P. Romano et al.

JOURNAL OF VIROLOGY (2011)

Add to Collection

Article Multidisciplinary Sciences

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals

Margaret Robinson et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Add to Collection

Article Biochemical Research Methods

XDS

Wolfgang Kabsch

ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)

Add to Collection

Article Biochemical Research Methods

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Paul D. Adams et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)

Add to Collection

Article Virology

Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance

Madhavi N. L. Nalam et al.

JOURNAL OF VIROLOGY (2010)

Add to Collection

Article Multidisciplinary Sciences

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

Keith P. Romano et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Add to Collection

Review Virology

Molecular Basis for Drug Resistance in HIV-1 Protease

Akbar Ali et al.

VIRUSES-BASEL (2010)

Add to Collection

Article Chemistry, Multidisciplinary

Phaser crystallographic software

Airlie J. McCoy et al.

JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)

Add to Collection

Article Biochemistry & Molecular Biology

Only one protomer is active in the dimer of SARS 3C-like proteinase

Hao Chen et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Add to Collection

Article Biochemical Research Methods

Coot:: model-building tools for molecular graphics

P Emsley et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)

Add to Collection

Article Medicine, General & Internal

A novel coronavirus associated with severe acute respiratory syndrome

TG Ksiazek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Add to Collection

Article Biochemistry & Molecular Biology

Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes

M Prabu-Jeyabalan et al.

STRUCTURE (2002)

Add to Collection

Article Immunology

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples

K Hertogs et al.

AIDS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.